Dynavax Technologies (NASDAQ:DVAX) Reaches New 1-Year Low - Should You Sell?

Key Points

• Dynavax Technologies' stock hit a new 52-week low at $9.20, down from a previous close of $9.41, with over 1 million shares traded.
• Despite the stock's decline, several Wall Street analysts have upgraded their ratings, with a consensus rating of "Moderate Buy" and a target price of $24.33.
• In the latest earnings report, Dynavax reported a profit of $0.14 EPS, exceeding analysts' expectations, alongside a revenue of $95.44 million for the quarter.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $9.20 and last traded at $9.27, with a volume of 1065095 shares changing hands. The stock had previously closed at $9.41.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities restated a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.33.

Dynavax Technologies Trading Down 0.6%

The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -21.07 and a beta of 1.24. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The business has a fifty day moving average of $10.48 and a two-hundred day moving average of $10.95.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.The business had revenue of $95.44 million for the quarter, compared to analysts' expectations of $87.55 million. As a group, equities analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of Dynavax Technologies stock in a transaction on Friday, August 22nd. The shares were bought at an average price of $10.82 per share, with a total value of $41,116.00. Following the purchase, the director directly owned 35,004 shares in the company, valued at $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Dynavax Technologies

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Choreo LLC increased its holdings in shares of Dynavax Technologies by 3.2% during the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock worth $452,000 after buying an additional 1,065 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company's stock worth $93,000 after buying an additional 1,226 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Dynavax Technologies by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock worth $401,000 after buying an additional 1,453 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dynavax Technologies by 1.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company's stock worth $1,126,000 after buying an additional 1,625 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies in the 1st quarter valued at $30,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.